Salarius Pharmaceuticals, Inc. (SLRX) is a leading late-stage biotherapeutics firm engaged in developing cancer therapeutics for oncology patients. The lead pipeline candidate of the company is Seclidemstat in Phase 1/2 clinical-stage used for treating prostate, breast, ovary cancer, and tumors.
The price of SLRX stock during the regular trading of March 9, 2022, was $0.37 with a decline of 2.40%. At the last check of the aftermarket, the stock rebounded by 13.3%.
SLRX: Events and Happenings
On March 03, 2022, SLRX updated that it will release its financials for the three months ended December 31, 2021, on March 10, 2022. The company will also host a conference call and webcast to discuss its corporate matters. On February 17, 2022, SLRX reported its Executive management’s participation at the Virtual Diamond Equity Research Emerging Growth Invitational 2022 Conference on February 24.
On February 08, 2022, SLRX announced its CEO’s virtual presence at the 2022 BIO CEO & Investor Conference held on February 14-17. On January 13, 2022, SLRX informed the press about its entry into a definitive contract with DeuteRx, LLC for the acquisition of a small molecule targeted protein degradation platform or SP-3164. On December 29, 2021, SLRX reported the achievement of a dosing milestone in seclidemstat Phase 1/2 trials. The company assessed its efficacy against Ewing sarcoma and FET-rearranged sarcomas and advanced to the second lead-in safety unit.
SLRX: Key Financials
On November 04, 2021, SLRX released its unaudited financial report for the third quarter of fiscal 2021 ended September 30, 2021. Some of the key updates are as follows.
Revenue
No revenue was recorded by the company for Q3 2021, while a grant revenue of $1.37 million was reported during the same period of 2020.
EPS
Net loss per share basic and diluted in the third quarter of 2021 was $3.7 million, or $0.08 compared to $1.7 million, or $0.10 in the corresponding quarter of 2020. The company experienced a substantial incline in its earnings per share over the year.
Conclusion
SLRX stock price dipped 74% in the last year as the restrictions were imposed globally during the pandemic. The company’s stock rebounded in aftermarket trading as it is gearing for the fourth quarter financial statement release. The revenue guidance provided by the company for the quarter is $325 thousand against -$0.08 EPS.
